President-elect Trump’s nomination of Robert F. Kennedy, Jr. to lead the Department of Health and Human Services ranks among his most controversial. The outcry against the Kennedy nomination began within minutes of the announcement. Much of the consternation regarding Kennedy’s nomination can be attributed to his criticisms of the Food and Drug Administration (FDA), which he has alleged is a “corrupt system.”
Among its multiple responsibilities, the FDA is charged with oversight of the cosmetics and skincare industry. The skincare market in the United States represents a rapidly growing $24 billion-a-year industry that is projected to surpass $30 billion by 2030. As some skincare treatments require the injection of products like dermal fillers and neuromuscular blocking agents, the safety of these products is no less important than in medicine.
Unfortunately, many cosmetic companies prioritize profit over safety, leading to the use of harmful ingredients, inadequate testing practices, and false advertising. While most consumers would expect that the products they use regularly are safe, numerous cosmetic products contain toxic ingredients that can cause serious and lasting health issues.
Beauty industry giants L’Oréal and Galderma have proven track records of ignoring consumer safety, and the announcement of L’Oréal’s recent major investment in Galderma, makers of Restylane and Dysport, raises serious concerns. Might a Secretary Kennedy find this arrangement problematic?
Read the full article here.
